: Biosynthesis of collagen molecules, as well as collagenous segments of non-collagen proteins, requires extensive post-translational modifications (PTMs) that confer specific functional and structural properties to tissues and organs. Within collagen polypeptide sequences, lysine residues are subject to a series of PTMs, resulting in hydroxylation and subsequent O-linked glycosylation of their side chains. These modifications are catalyzed by two distinct metalloenzyme families, named LH/PLOD and GLT25D/COLGALT, which alternatively process modified lysine side chains yielding 5-hydroxylysine (LH/PLOD), β-(1,O)-galactosyl-5-hydroxylysine (GLT25D/COLGALT), and α-(1,2)-glucosyl-β-(1,O)-galactosyl-5-hydroxylysine (LH/PLOD). In this chapter, we illustrate strategies to recombinantly produce human full-length LH3/PLOD3 as well as GLT25D1/COLGALT1, verify the quality of these recombinant preparations, and perform direct and indirect assays to evaluate their enzymatic activities in vitro on synthetic collagen peptides and gelatin.
Recombinant Production and Characterization of Human Enzymes Responsible for Collagen Lysine Post-translational Modifications
Mattoteia, Daiana;De Marco, Matteo;Rai, Sristi Raj;Faravelli, Silvia;Scietti, Luigi;Forneris, Federico
2026-01-01
Abstract
: Biosynthesis of collagen molecules, as well as collagenous segments of non-collagen proteins, requires extensive post-translational modifications (PTMs) that confer specific functional and structural properties to tissues and organs. Within collagen polypeptide sequences, lysine residues are subject to a series of PTMs, resulting in hydroxylation and subsequent O-linked glycosylation of their side chains. These modifications are catalyzed by two distinct metalloenzyme families, named LH/PLOD and GLT25D/COLGALT, which alternatively process modified lysine side chains yielding 5-hydroxylysine (LH/PLOD), β-(1,O)-galactosyl-5-hydroxylysine (GLT25D/COLGALT), and α-(1,2)-glucosyl-β-(1,O)-galactosyl-5-hydroxylysine (LH/PLOD). In this chapter, we illustrate strategies to recombinantly produce human full-length LH3/PLOD3 as well as GLT25D1/COLGALT1, verify the quality of these recombinant preparations, and perform direct and indirect assays to evaluate their enzymatic activities in vitro on synthetic collagen peptides and gelatin.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


